1 Min Read
Sept 8 (Reuters) - Celgene Corp
* Data presented at ESMO 2017 further evaluate role of Abraxane® for patients with historically challenging cancers Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.